Skip to Content

Myfortic (mycophenolic acid) Disease Interactions

There are 6 disease interactions with Myfortic (mycophenolic acid):

Major

Immunosuppressive agents (applies to Myfortic) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.

Major

Immunosuppressive agents (applies to Myfortic) PML

Major Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency

Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML). Certain agents are contraindicated in patients who have or have had PML. Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents. Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML. Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.

Major

Mycophenolic acid (applies to Myfortic) HGPRT deficiency

Major Potential Hazard, Moderate plausibility. Applicable conditions: Lesch-Nyhan Syndrome, Gout

The use of mycophenolic acid should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes because it may cause an exacerbation of disease symptoms.

Major

Mycophenolic acid (applies to Myfortic) vaccination

Major Potential Hazard, Moderate plausibility.

The use of live attenuated vaccines should be avoided during treatment with mycophenolic acid; examples include (but not limited to) the following: intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines.

Moderate

Mycophenolic acid (applies to Myfortic) GI complications

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Hemorrhage, Gastrointestinal Perforation, Esophageal Ulceration, Peptic Ulcer with Hemorrhage

The use of mycophenolic acid may cause gastrointestinal bleeding (requiring hospitalization), intestinal perforations, gastric ulcers, and duodenal ulcers. Mycophenolic acid should be administered with caution in patients with active serious digestive system disease.

Moderate

Mycophenolic acid (applies to Myfortic) skin cancer

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Lymphoma

The use of mycophenolic acid increases the risk of developing lymphomas and other malignancies, particularly of the skin. Patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor. Care should be exercised when using mycophenolic acid in patients with these conditions.

Myfortic (mycophenolic acid) drug interactions

There are 278 drug interactions with Myfortic (mycophenolic acid)

Myfortic (mycophenolic acid) alcohol/food interactions

There are 2 alcohol/food interactions with Myfortic (mycophenolic acid)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.